Ivano-Frankivsk

The trials here

What the 27 trials at this site are about, from their registry records.

Conditions

• Lung cancer6 trials
• Chronic kidney disease4 trials
• Asthma3 trials
• COPD3 trials
• Heart failure2 trials
• High blood pressure2 trials
• Ovarian cancer2 trials
• Atrial fibrillation1 trial
• Bladder cancer1 trial
• Cervical cancer1 trial
• Chronic lymphocytic leukaemia1 trial
• Colorectal cancer1 trial
• and 10 more

Phase

• Phase 319 trials
• Phase 26 trials
• Phase 1/21 trial
• Phase 41 trial

Status

• Active, not recruiting8 trials
• Recruiting7 trials
• Completed6 trials
• Not yet recruiting3 trials
• Terminated3 trials

Lead sponsor

• AstraZeneca24 trials
• Acerta Pharma BV1 trial
• EMD Serono Research & Development Institute, Inc.1 trial
• Otsuka Pharmaceutical Development & Commercialization, Inc.1 trial

Running trials

• Recruiting

  A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

  NCT07624305· Phase 3· AstraZeneca· Source

  Contact: AstraZeneca Clinical AstraZeneca Clinical

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.

  NCT07619131· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

  NCT07276581· Phase 2· AstraZeneca· Source

• Recruiting

  A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

  NCT07082738· Phase 2· AstraZeneca· Source

• Recruiting

  Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

  NCT06677060· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

  NCT06742723· Phase 3· AstraZeneca· Source

• Recruiting

  Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

  NCT06307652· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

  NCT06268873· Phase 3· AstraZeneca· Source

• Recruiting

  A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  NCT06283966· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

  NCT06023589· Phase 3· AstraZeneca· Source

• Active, not recruiting

  D9319C00001- 1L OC Mono Global RCT

  NCT04884360· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

  NCT04644068· Phase 1/2· AstraZeneca· Source

• Active, not recruiting

  Savolitinib vs. Sunitinib in MET-driven PRCC.

  NCT03091192· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

  NCT03164616· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

  NCT03043872· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

  NCT02970318· Phase 3· Acerta Pharma BV· Source

• Active, not recruiting

  Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

  NCT02542293· Phase 3· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease3 recruiting
• COPD2 recruiting
• Heart failure2 recruiting
• Asthma1 recruiting
• High blood pressure1 recruiting
• Rheumatoid arthritis1 recruiting

Closed trials

• Completed

  A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations

  NCT06529419· Phase 2· AstraZeneca· Source

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT06040086· Phase 3· AstraZeneca· Source

• Completed

  Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

  NCT05251259· Phase 2· AstraZeneca· Source

• Terminated

  Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

  NCT04847232· Phase 3· AstraZeneca· Source

• Terminated

  A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia

  NCT04109950· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Completed

  Durvalumab Long-Term Safety and Efficacy Study

  NCT04078152· Phase 4· AstraZeneca· Source

• Terminated

  A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis

  NCT02975349· Phase 2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

  NCT02937818· Phase 2· AstraZeneca· Source

• Completed

  A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.

  NCT01602380· Phase 3· AstraZeneca· Source